All In Biotech

Drug Trial Radar · NCT05953831

Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy

Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodeling in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Apr 30, 2024

Primary completion

Sep 30, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Cardior Pharmaceuticals GmbHIndustry
Sponsor type
Industry
First posted
Jul 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study including approximately 130 randomized HF patients with heart failure with mildly reduced or preserved ejection fraction (LVEF ≥45%), to assess efficacy and safety of CDR132L on reverse remodeling. In this study, patients with HFpEF (EF ≥50%) or HFmrEF (LVEF 45-49%) will be included.

Conditions

  • Heart Failure With Preserved Ejection Fraction

Interventions

  • CDR132LDrug

    CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.

  • PlaceboDrug

    Placebo to CDR132L

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Left ventricular massTime frame: 6 months
  2. Left atrial maximum volumeTime frame: 6 months
  3. Total cardiac extracellular volumeTime frame: 6 months
  4. Left atrial strainTime frame: 6 months
  5. Maximum left ventricular wall thicknessTime frame: 6 months
  6. Age-adjusted e' velocityTime frame: 6 months
  7. Global longitudinal strainTime frame: 6 months
  8. E/e'Time frame: 6 months
  9. Concentration of N-terminal pro B-type natriuretic peptideTime frame: 6 months
  10. Concentration of high-sensitivity cardiac troponin TTime frame: 6 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.